4-Year Loss of Ambulation Data Demonstrates Sarepta's (SRPT) Eteplirsen Benefit - Oppenheimer
April 20, 2016 6:59 AM
Oppenheimer analyst Christopher Marai on Sarepta Therapeutic (NASDAQ: SRPT) after the company presented four-year data, recently submitted as part of ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
